About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Department of Hematology
›
top-articles
Department of Hematology
105
(top 1%)
papers
4.6K
(top 1%)
citations
25
(top 1%)
h
-index
68
(top 1%)
g
-index
106
all documents
4.8K
doc citations
1.1K
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Blood
2013
1,743
2
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
Leukemia
2009
808
3
BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships
Blood
2013
187
4
Vitamin D modulation of innate immune responses to respiratory viral infections
Reviews in Medical Virology
2017
176
5
Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation
International Journal of Cancer
2006
153
6
The Haemostatic Role of Tissue Factor Pathway Inhibitor
Arteriosclerosis, Thrombosis, and Vascular Biology
2008
128
7
The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia
Blood
2007
126
8
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies
Haematologica
2011
114
9
Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia
Blood
2009
113
10
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
Leukemia
2010
97
11
Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation
Annals of Oncology
2013
89
12
Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients
Biology of Blood and Marrow Transplantation
2011
82
13
International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)
Blood
2008
80
14
Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients
Bone Marrow Transplantation
2003
62
15
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
British Journal of Pharmacology
2009
56
16
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
Leukemia
2012
48
17
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma
Blood
2010
43
18
The role of markers of bone remodeling in multiple myeloma
Blood Reviews
2005
41
19
GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder
British Journal of Haematology
2005
37
20
Anergic T cells exert antigen-independent inhibition of cell-cell interactions via chemokine metabolism
Blood
2003
36
21
A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML
Blood
2017
35
22
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Blood
2012
34
23
Initial treatment for patients with CML
Hematology American Society of Hematology Education Program
2009
29
24
Design of optimal patient-specific chemotherapy protocols for the treatment of acute myeloid leukemia (AML)
Computers and Chemical Engineering
2013
27
25
Donor Lymphocyte Infusions (DLI) After Peripheral Blood Stem Cell Transplantation. A Retrospective Analysis of 357 Patients by the Chronic Leukemias Working Party EBMT.
Blood
2009
26
26
Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party
Leukemia
2007
25
27
A Real-Time Multi-Channel Monitoring System for Stem Cell Culture Process
IEEE Transactions on Biomedical Circuits and Systems
2008
25
28
EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure
Biology of Blood and Marrow Transplantation
2012
25
29
Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation
Haematologica
2013
25
30
Bisphosphonate treatment for multiple myeloma
Drugs of Today
2004
25
31
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation
2021
24
32
Human Invariant NKT Cells Display Alloreactivity Instructed by Invariant TCR-CD1d Interaction and Killer Ig Receptors
Journal of Immunology
2008
23
33
Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro
Experimental Hematology
2004
19
34
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia
British Journal of Haematology
2006
17
35
Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.
Blood
2010
17
36
Humoral and Cellular Immunity to Primary H1N1 Infection in Patients with Hematologic Malignancies following Stem Cell Transplantation
Biology of Blood and Marrow Transplantation
2011
14
37
MicroRNA-181a* Targets Nanog in a Subpopulation of CD34+ Cells Isolated From Peripheral Blood
Molecular Therapy - Nucleic Acids
2012
14
38
A Short-activating RNA Oligonucleotide Targeting the Islet β-cell Transcriptional Factor MafA in CD34+ Cells
Molecular Therapy - Nucleic Acids
2013
13
39
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)
Annals of Oncology
2017
13
40
Health-care professionals’ perspective on discussing sexual issues in adult patients after haematopoietic cell transplantation
Bone Marrow Transplantation
2018
13
41
Can we include vaccines with stem-cell transplantation?
Nature Reviews Clinical Oncology
2009
12
42
Optimization of in vitro erythropoiesis from CD34+ cord blood cells using design of experiments (DOE)
Biochemical Engineering Journal
2011
12
43
Ceramic Hollow Fibre Constructs for Continuous Perfusion and Cell Harvest from 3D Hematopoietic Organoids
Stem Cells International
2018
11
44
Simulation of ex vivo bone marrow culture: Application to chronic myeloid leukaemia growth model
Biochemical Engineering Journal
2012
10
45
Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.
Blood
2009
10
46
First use of myeloid colony-stimulating factors in humans
Bone Marrow Transplantation
2013
8
47
Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival
Blood
2008
7
48
Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia
Future Oncology
2011
6
49
Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.
Blood
2010
6
50
Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial
Blood
2012
6
site/software ©
exaly
; All materials licenced under
CC by-SA
.